Key Takeaways
- A class action lawsuit has been filed against Sana Biotechnology, Inc. for alleged securities law violations during the Class Period of March 17, 2023, to November 4, 2024.
- The lawsuit claims that Sana made misleading statements about its financial health and product funding, affecting investor decisions.
- Investors with losses in Sana can request lead plaintiff status until May 20, 2025, and there are no upfront costs for representation.
Class Action Filed Against Sana Biotechnology
Bronstein, Gewirtz & Grossman, LLC has launched a class action lawsuit against Sana Biotechnology, Inc. (NASDAQ: SANA) and several of its officers on behalf of investors. The lawsuit aims to recover damages resulting from alleged violations of federal securities laws for those who purchased or otherwise acquired Sana securities between March 17, 2023, and November 4, 2024.
The complaint alleges that during the Class Period, the defendants issued false and misleading statements concerning Sana’s business operations and financial prospects. Key accusations include claims that Sana was significantly at risk of not having enough funds to continue operations or advance its product candidates. The lawsuit asserts that the company’s product candidates—specifically SC291 in oncology, SC379, and SG299—were not as promising as represented to investors.
Furthermore, the defendants allegedly failed to disclose that Sana would likely need to reduce funding for these product candidates or even discontinue them to focus on more promising options, which could result in significant layoffs. As a consequence, the lawsuit asserts that the defendants overstated Sana’s financial stability and capacity to operate, leading to materially false or misleading public statements at all relevant times.
Investors who believe they have suffered losses due to these alleged misstatements are encouraged to join the lawsuit by visiting the firm’s website. A copy of the complaint is available for review there. Interested parties can also reach out to Peretz Bronstein, Esq. or Client Relations Manager Nathan Miller at Bronstein, Gewirtz & Grossman, LLC for further information. Investors have until May 20, 2025, to file for lead plaintiff status, although participation in any recovery does not necessitate serving as the lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis for these class actions, meaning that fees and expenses will only be sought if the case is successful. The firm has a strong track record of representing investors in securities fraud cases and has recovered substantial amounts for clients nationwide.
The content above is a summary. For more details, see the source article.